baclofen has been researched along with Mucopolysaccharidosis II in 1 studies
Mucopolysaccharidosis II: Systemic lysosomal storage disease marked by progressive physical deterioration and caused by a deficiency of L-sulfoiduronate sulfatase. This disease differs from MUCOPOLYSACCHARIDOSIS I by slower progression, lack of corneal clouding, and X-linked rather than autosomal recessive inheritance. The mild form produces near-normal intelligence and life span. The severe form usually causes death by age 15.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horn, F | 1 |
| Petrík, M | 1 |
| Dúbravová, D | 1 |
| Hornová, J | 1 |
| Brennerová, K | 1 |
| Bzduch, V | 1 |
1 other study available for baclofen and Mucopolysaccharidosis II
| Article | Year |
|---|---|
Intrathecal baclofen in mucopolysaccharidosis type II (Hunter syndrome): case report.
Topics: Baclofen; Child; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Mucopolysaccharidosi | 2018 |